This article discusses pharmaceutical pricing and reimbursement policies in European
countries with regard to their ability to ensure affordable access to medicines. A frequently …

We review the recent literature on financing biomedical innovation, with a specific focus on
the drug development process and how it may be enhanced to improve outcomes. We begin …

This paper argues that incumbent firms may acquire innovative targets solely to discontinue
the target's innovation projects and preempt future competition. We call such acquisitions …

Innovation is central to long-run economic growth. This chapter summarizes the state of the
literature on the economics of innovation, highlighting open policy questions. We first …

Abstract Analysis of the timing of launches of 642 new drugs in 76 countries during 1983–
2002 shows that patent and price regulation regimes strongly affect how quickly new drugs …

Although marketing scholars often seek to contribute new knowledge that is applicable
across industries, some industries have unique characteristics that require industry-specific …

Motivated by the recent establishment of major US federal programs seeking to harness the
potential of regional innovation ecosystems, we assess the promise and challenges of place …

In recent years policy-makers in European countries have been increasingly concerned
about developments in the pharmaceutical sector that have been challenging the …

Consumers constantly confront intellectual property rights (IPRs) every day, from their
morning cup of Starbucks coffee to the Intel chip on their computer at work. Intellectual …

OBJECTIVE: This study aimed to provide an up-to-date description as well as comparative
analysis of the national characteristics of pharmaceutical external price referencing (EPR) in …